Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal



Persistence. Acamprosate is potentially persistent.

Bioaccumulation. Acamprosate has low potential for bioaccumulation.

Toxicity. Acamprosate has low acute toxicity. See comment about this under "Detailed information".

Risk. The use of acamprosate (sales data Sweden 2018) has been considered to result in insignificant environmental risk.


This summary information comes from Fass.

Detailed information

Fass environmental information

Fass environmental information for Campral (akamprosat) from Merck (downloaded 2023-03-15).


Persistence: Biotic degradation. Ready degradability: Test results 5.6 % degradation in 28 days (guideline FDA TAD 3.11). ... Abiotic degradation. Hydrolysis: Test results < 10 % degradation in 5 days (guideline FDA TAD 3.09). Akamprosat is not readily biodegradable and undergoes no hydrolysis. The phrase “Akamprosat is potentially persistent” is thus chosen.

Bioaccumulation: Log Kow = -2.83 at approx. pH 7 (guideline FDA TAD 3.02).

Acute toxicity: There are data for 3 trophic levels, most sensitive crustacean (Daphnia magna) EC50 48h (Immobilization) = > 989 mg/L (guideline FDA TAD 4.08). Comment: Values reported as greater than are not according to the guidelines. The actual value may be lower.


PEC/PNEC is based on sales data in Sweden in year 2018. PEC/PNEC = 0.00024 which gives the risk insignificant.

Author: Health and Medical Care Administration, Region Stockholm